JP2023523253A5 - - Google Patents
Info
- Publication number
- JP2023523253A5 JP2023523253A5 JP2022564443A JP2022564443A JP2023523253A5 JP 2023523253 A5 JP2023523253 A5 JP 2023523253A5 JP 2022564443 A JP2022564443 A JP 2022564443A JP 2022564443 A JP2022564443 A JP 2022564443A JP 2023523253 A5 JP2023523253 A5 JP 2023523253A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- approximately
- rhsp
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013726P | 2020-04-22 | 2020-04-22 | |
| US63/013,726 | 2020-04-22 | ||
| US202063072354P | 2020-08-31 | 2020-08-31 | |
| US63/072,354 | 2020-08-31 | ||
| PCT/US2021/028207 WO2021216584A1 (en) | 2020-04-22 | 2021-04-20 | Use of surfactant protein d to treat viral infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023523253A JP2023523253A (ja) | 2023-06-02 |
| JP2023523253A5 true JP2023523253A5 (https=) | 2024-05-02 |
| JP7798791B2 JP7798791B2 (ja) | 2026-01-14 |
Family
ID=78270057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564443A Active JP7798791B2 (ja) | 2020-04-22 | 2021-04-20 | ウイルス感染症の治療のための肺サーファクタントタンパク質ｄの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230181697A1 (https=) |
| EP (1) | EP4138905A4 (https=) |
| JP (1) | JP7798791B2 (https=) |
| KR (1) | KR20230019089A (https=) |
| AU (1) | AU2021258178A1 (https=) |
| BR (1) | BR112022021423A2 (https=) |
| CA (1) | CA3180205A1 (https=) |
| IL (1) | IL297362A (https=) |
| MX (1) | MX2022013195A (https=) |
| WO (1) | WO2021216584A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2023145916A1 (https=) * | 2022-01-31 | 2023-08-03 | ||
| WO2024097169A1 (en) * | 2022-11-01 | 2024-05-10 | National Jewish Health | Treatment of coronavirus infections with antimicrobial phospholipid compositions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8933032B2 (en) * | 1998-10-20 | 2015-01-13 | Children's Hospital Medical Center | Surfactant protein D for the treatment of disorders associated with lung injury |
| US20030221199A1 (en) | 1998-10-20 | 2003-11-27 | Whitsett Jeffrey A. | Surfactant protein D for the prevention and diagnosis of pulmonary emphysema |
| US20120220531A1 (en) * | 2011-02-04 | 2012-08-30 | Cincinnati Children's Hospital Medical Center | Surfactant protein d for the treatment of disorders associated with lung injury |
| US20130216499A1 (en) * | 2012-02-17 | 2013-08-22 | Wenlin Huang | Compositions of recombinant human endostatin adenovirus injections and methods of production |
| NL2011626C2 (en) * | 2013-10-17 | 2015-04-20 | Stichting Tech Wetenschapp | Novel polypeptide and uses thereof. |
| JP7797098B2 (ja) * | 2018-03-29 | 2026-01-13 | エアウェイ・セラピューティクス・インコーポレイテッド | サーファクタントタンパク質ｄ（ｓｐ－ｄ）を含む方法及び組成物 |
| WO2020247675A1 (en) * | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
| KR102205028B1 (ko) * | 2020-03-22 | 2021-01-20 | (주)셀트리온 | 사스-코로나바이러스-2에 중화 활성을 갖는 결합 분자 |
| US11123329B1 (en) * | 2020-03-23 | 2021-09-21 | Vicore Pharma Ab | Use of angiotensin II type 2 receptor agonist |
| CN112481417B (zh) * | 2020-12-24 | 2022-05-27 | 山西大学 | 新冠肺炎病毒分型及突变位点快速检测方法及试剂盒 |
-
2021
- 2021-04-20 AU AU2021258178A patent/AU2021258178A1/en active Pending
- 2021-04-20 BR BR112022021423A patent/BR112022021423A2/pt unknown
- 2021-04-20 IL IL297362A patent/IL297362A/en unknown
- 2021-04-20 CA CA3180205A patent/CA3180205A1/en active Pending
- 2021-04-20 WO PCT/US2021/028207 patent/WO2021216584A1/en not_active Ceased
- 2021-04-20 US US17/920,245 patent/US20230181697A1/en active Pending
- 2021-04-20 MX MX2022013195A patent/MX2022013195A/es unknown
- 2021-04-20 KR KR1020227040749A patent/KR20230019089A/ko not_active Withdrawn
- 2021-04-20 EP EP21792923.1A patent/EP4138905A4/en active Pending
- 2021-04-20 JP JP2022564443A patent/JP7798791B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1523997B (zh) | 稳定的白介素2 | |
| JP2023523253A5 (https=) | ||
| Asselah et al. | Interferon free therapy with direct acting antivirals for HCV | |
| JP3031570B2 (ja) | 安定化されたゴナドトロピンを含有する調製品 | |
| Gentile et al. | A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir | |
| KR950014915B1 (ko) | 탈시알로당단백-포함화합물 | |
| Jakeman et al. | Exacerbation of bacterial toxicity to infant ferrets by influenza virus: possible role in sudden infant death syndrome | |
| JP5539363B2 (ja) | インターフェロンおよびリバビリンとのｈｃｖｎｓ３プロテアーゼ阻害剤の組合せ | |
| JP2024099628A5 (https=) | ||
| RU2020131642A (ru) | Способы и композиции, содержащие сурфактантный белок d (sp-d) | |
| RU2011127913A (ru) | Составы, содержащие антитела | |
| JP2024503265A5 (https=) | ||
| JP2022539077A5 (https=) | ||
| TWI893108B (zh) | 司馬魯肽在醫學上的用途 | |
| JP2007522237A5 (https=) | ||
| US10344055B2 (en) | Composition comprising a peptide and an inhibitor of viral neuraminidase | |
| EP4203937A1 (en) | Formulations of anti-viral compounds | |
| JP2023539476A5 (https=) | ||
| EP2119451A1 (en) | Lyophilized preparation comprising influenza vaccine, and method for preparation thereof | |
| JP2022062153A5 (https=) | ||
| US20240148820A1 (en) | Anti-viral peptides and compositions and methods of use thereof | |
| JP2025525989A5 (https=) | ||
| US20140363396A1 (en) | Once daily treatment of hepatitis c with ribavirin and taribavirin | |
| JP7798791B2 (ja) | ウイルス感染症の治療のための肺サーファクタントタンパク質ｄの使用 | |
| García-Herrera et al. | Effect of lipopolysaccharide on D-fructose transport across rabbit jejunum |